EXERCISE 3 CRITERIA FOR DELETION OF DRUGS FROM PNDF

THE COMMUNITY PHARMACY PROFILE

TRADITIONAL MARKET A more effective or equally effective but less toxic drug
DRUGSTORE becomes available
PERSONNEL The therapeutic efficacy of drug is found to be
STORE HOURS unsatisfactory or questionable
NON-TRADITIONAL MARKET Toxicity/suspected toxicity or potential for abuse or
STORE FRONT LAYOUTS dangerous interactions outweigh its therapeutic value
DRUGSTORE CHAIN OPERATION Disuse of drug and no longer available
MERCHANDISE &SERVICES The drug is no longer deemed cost-effective to other
therapies
WAYS OF DEVELOPING COMPETITIVE ADVANTAGES IN The drug is a fixed dose combination which does not
COMMUNITY PHARMACY satisfy the requirements of AO 96 s. 1990
Product line assortment
Leader pricing strategy CORE LIST
Innovation of operation
Customer services
Acetylcysteine Ergocalciferol
Equipment /facilities
Azathioprine Fluorecein
COMPARISON OF COMMUNITY PHARMACY IN 1990S
AND 2000S Clofazimine Folic acid
Location Cobra antivenin Hydrochlorthiazide
signboards
Store front and interiors Dantrolene Hydrocortisone
Staffing pattern
Diazepam Hydroxycobalamine
Pharmacist
Communication Diethylcarbamazepi Indomethacin inj
Store facilities ne
Capitalization
Transportation Diphtheria-tetanus Iodine
toxoids
Exercise 4 Dimercaprol INH + ethambutol
THERAPEUTIC CATEGORIES OF DRUGS BY PNDF
PNDF endrophonium INH + rifampicin
DANGEROUS DRUGS
INH+ Rifampicin+ Praziquantrel
BFAD
PZA
THERAPEUTIC COMMITTEES
CORE/ MAIN LIST Levodopa + Retinol
COMPLEMENTARY LIST Thiacetazone

GENERAL GUIDELINES FOR ESTABLISHING PNDF Lorazepam Na Ca edetate

Relevance to disease Methylene blue NaI 131I
Efficacy and safety
Quality N-acetyl Na nitrite
Cost penicillamine
Appropriateness to capability of health workers Neostigmine Na nitroprusside
at different levels of health care
Local health problems Nicotinamide Na thiosulfate
Benefit/risk ratio
ORS 75 Succimer
Preferential factors for evaluating
replacement
therapeutically equivalent drugs
Drugs formulated as single compounds Potassium Thiamine
Period review of drug list
Pot. phosphate Tuberculin purified
CRITERIA FOR INCLUSION OF DRUGS INTO PNDF protein derivative
Drug is needed for prevention and Tx of conditions not
already covered in existing list
Drug is more effective / less toxic than the drug listed
for same medication
Drug is at least as effective and safe and of lower cost
than the drug listed for same indication
Drug is essential for specific DOH health project
COMPLEMENTARY LIST
Aciclovir eye ointment Hydroxycobalamin
Alpha-tocopherol Indomethacin
Al acetate Iodamide
Cromolyn Iron dextran
Buserelin Povidone iodide
Busulfan Pralidoxime Cl
Chloral hydrate Pyrimethamine
Chlormethine Recombinant tissue
plasminogen activator
Dithranol Rifabutin
estramustine Rose bengal
Silver nitrate Varicella zoster Ig
Spectinomycin Vasopressin
Terizodone Yerba buena
Tetracosactide Zinc
Thiacetazone

DRUGS IN PNDF WITH SPECIAL REQUIREMENTS

Dangerous Drugs (A1)

Alprazolam Morphine
Bromazepam Nalbuphine
Butorphanol Oxycodone
Clonazepam Pethidine (meperidine)
Codein Phenobarbital
Diazepam Thiopenthal Na
Fentanyl Tramadol
Lorazepam Zolpidem
Methylphenidate
midazolam

Controlled precursors and Essential chemicals (A2)

Ephedrine
Ergotamine
PPA

MEDICINAL PRODUCTS LISTED WITH BFAD

Akapulko
Lagundi
Sambong
Tsaang gubat
Yerba buena